Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 10/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796471 | 0.83 | MTNR1A (0.47) | MTNR1AMTNR1BERN1THRB | |
| SCHEMBL19804198 | 0.83 | MTNR1A (0.39) | MTNR1AMTNR1BBAZ2BBAZ2ATHRB | |
| SCHEMBL19801688 | 0.82 | EGFR (0.38) | MTNR1AMTNR1BBAZ2BBAZ2APTGER4 | |
| SCHEMBL19804617 | 0.82 | EGFR (0.38) | MTNR1AMTNR1BBAZ2BBAZ2APTGER4 | |
| SCHEMBL19624474 | 0.81 | MTNR1A (0.40) | MTNR1AMTNR1BBAZ2BBAZ2AERN1 | |
| SCHEMBL19804635 | 0.80 | MTNR1A (0.44) | MTNR1AMTNR1BERN1 | |
| SCHEMBL19804025 | 0.80 | THRB (0.40) | MTNR1AMTNR1BBAZ2BBAZ2AERN1 | |
| SCHEMBL19804031 | 0.79 | THRB (0.38) | THRBPTGER4 | |
| SCHEMBL19796458 | 0.78 | THRB (0.38) | MTNR1AMTNR1BTHRBPTGER4 | |
| SCHEMBL19804311 | 0.78 | FFAR1 (0.36) | MTNR1AMTNR1BBAZ2BBAZ2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | MTNR1A 4362/4885MTNR1B 4638/4885NPC1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.